New Preclinical Data on AI-Generated Target Identified in BenevolentAI and AstraZeneca Collaboration Presented at ATS 2023

Research, presented by AstraZeneca, provides information on the biological validation of Serum Response Factor as a potential target for idiopathic pulmonary fibrosis The target was discovered

Related Keywords

London ,City Of ,United Kingdom ,New York ,United States ,Rajin Kang ,Astrazeneca ,International Conference ,Vp Communications ,Serum Response Factor ,Benevolent Platform ,Euronext Amsterdam ,Artificial Intelligence ,Central Profibrotic Mechanism ,Idiopathic Pulmonary Fibrosis ,Gefallene Big Techs ,Preclinical ,Data ,Enerated ,Target ,Dentified ,Benevolentai ,Collaboration ,Resented ,023 ,